Clinical Significance of Plasma Protease C1 Inhibitor in Latent Autoimmune Diabetes in Adults
10.3969/j.issn.0253-9896.2014.05.016
- VernacularTitle:成人隐匿性自身免疫性糖尿病早期血浆SERPING1的变化及意义
- Author:
Wen QIN
;
Jiali ZHANG
;
Ning XIA
- Publication Type:Journal Article
- Keywords:
diabetes mellitus,type 1;
diabetes mellitus,type 2;
ROC curve;
latent autoimmune diabetes in adults;
plasma protease C1 inhibitor
- From:
Tianjin Medical Journal
2014;(5):458-461
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine plasma levels of protease C1 inhibitor (SERPING1) in adult patients with latent autoimmune diabetes (LADA), and their clinical significance thereof. Methods The levels of SERPING1 were detected and compared between LADA, type 1 diabetes (T1DM), type 2 diabetes (T2DM) and healthy control groups. The correlation between plasma levels of SERPING1 and other clinical indicators such as age, disease course, glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG), 2 h postprandial plasma glucose (2 hPG), fasting c-peptide (FCP) and 2 h postprandi-al C peptide (2 hCP) was analyzed. Multi-factor regression analysis and receiver operating characteristic (ROC) were used to evaluate the predictive effect of SERPING1 in LADA at the early stage. Results The level of SERPING1 was significantly higher in LADA group than that of T2DM group and control group (P < 0.05). There was a negative correlation between SERPING1 and FCP, and a positive correlation between SERPING1 and HbA1c, FPG and 2 hPG (P<0.05). There were no significant correlation between SERPING1 and age, disease course and 2 hCP. FCP was analyzed by regression equation (P<0.05), and which was the main influence factor of the plasma level of SERPING1. The area under the ROC curve (AUC) of SERPING1 was 0.613 (P<0.05), 95%CI 0.514-0.712. The optimal cut-point of SERPING1 for early prediction of LADA was 289.71 mg/L, and the sensitivity and specificity were 69%and 48%respectively. Conclusion SERPING1 combined with other indicators will be useful for identifying LADA from T2DM at the early stage.
